Clinical Trial Update: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates nivolumab with or without ipilimumab in mismatch repair–deficient (dMMR) recurrent endometrial cancer and is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Cancer
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Dedifferentiated Carcinoma
• Endometrial Endometrioid Adenocarcinoma
• Endometrial Mucinous Adenocarcinoma
• Endometrial Undifferentiated Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Status: RECRUITING